Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional cemiplimab in cutaneous squamous cell carcinoma and basal cell carcinoma
NCT03889912Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events and 1 more. Started Apr 2019; status: completed.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03889912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889912.